Dylann Cohn-Emery

Articles

Tislelizumab Plus Nab-Paclitaxel Yields Preliminary Efficacy in NMBIC

May 18th 2022

The combination of tislelizumab plus nab-paclitaxel demonstrated benefit and a tolerable safety profile in patients with high-risk non–muscle invasive bladder cancer.

Neoadjuvant Tislelizumab/Nab-Paclitaxel Combo Produces Early Activity in MIBC

May 16th 2022

The combination of neoadjuvant tislelizumab and nab-paclitaxel elicited a high rate of pathologic complete response in patients with muscle-invasive bladder cancer, according to preliminary findings from the phase 2 TRUCE-01 trial.

JSP191 Plus Fludarabine and Low-Dose Irradiation Produces Promising Early Data in MDS/AML

April 27th 2022

The combination of JSP191, fludarabine, and low-dose total body irradiation demonstrated facilitation of full donor myeloid chimerism, clearance of minimal residual disease, and a tolerable safety profile in patients with myelodysplastic syndrome or acute myeloid leukemia.

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors

April 13th 2022

The addition of SOT101, an interleukin-2/IL-15 Rβγ superagonist, to Pembrolizumab generated a clinical benefit and encouraging safety data in patients with advanced solid tumors.

Frontline Nivolumab/Cabozantinib Combo Maintains Long-Term OS Benefit in RCC

February 19th 2022

The combination of nivolumab plus cabozantinib elicited a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma.

Pembrolizumab Plus BSC Produces Improved OS in Advanced HCC

January 21st 2022

The combination of pembrolizumab plus best supportive care elicited improved overall survival and overall response rates as second-line therapy in patients from Asia with advanced hepatocellular carcinoma.

Toxicity Burden Decreased With Acalabrutinib Vs Ibrutinib in CLL

December 14th 2021

Acalabrutinib demonstrated a lower incidence of cardiovascular-related toxicities and a lower overall toxicity burden compared with ibrutinib in patients with chronic lymphocytic leukemia.

Phase 3 Trial Set to Evaluate Venetoclax Plus Acalabrutinib or Obinutuzumab in Treatment-Naive CLL/SLL

December 12th 2021

The combinations of venetoclax plus acalabrutinib or obinutuzumab will be evaluated in the phase 3 MAJIC trial.

Likelihood of Pathologic CR After Neoadjuvant Chemo is Not Significantly Affected by Race in Breast Cancer

December 10th 2021

Pathologic complete response and event-free survival was not found to be significantly affected by race among patients with high-risk breast cancer who received neoadjuvant chemotherapy; however, disparities were observed among patients who did not achieve a pCR.

Nivolumab/Cabozantinib Combo Yields Efficacy Regardless of Prior Nephrectomy in RCC

September 17th 2021

Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.

Challenges Remain in Treatment of Accelerated Phase Myeloproliferative Neoplasms

September 10th 2021

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Future of PV Treatments Centers Around More Tailored Approaches

September 9th 2021

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

HER2 Positivity at Diagnosis Shows Better PFS Benefit With HER2-Based Therapies Vs Negative Status in Breast Cancer

July 12th 2021

The median progression-free survival benefit experienced by patients with metastatic breast cancer who were HER2 positive at initial diagnosis and who were receiving standard HER2-directed therapies proved to be more favorable than what was reported in those who were HER2 negative and switched to HER2 positive status.

Tislelizumab, TTF Studies Poised to Address HCC Questions

July 2nd 2021

The optimal sequence of therapies in the second- or later-line settings for patients with hepatocellular carcinoma remains unclear.

Adagrasib/Cetuximab Combo in KRAS G12C+ CRC Under Exploration

July 1st 2021

The combination of adagrasib and cetuximab is being investigated in patients with previously treated, advanced, KRAS G12C–mutant colorectal cancer in the international, phase 3 KRYSTAL-10 study.

Neoadjuvant Pertuzumab Plus Trastuzumab/Nab-Paclitaxel Achieves 64% pCR With Less Toxicity in HER2+ Breast Cancer

June 6th 2021

Pertuzumab plus trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer induced a pathologic complete response similar to that achieved with docetaxel, carboplatin, trastuzumab, and pertuzumab, with less treatment-related toxicities.

Pralsetinib Elicits Durable Anti-Tumor Effects in RET Fusion+ Solid Tumors

June 5th 2021

Pralsetinib demonstrated robust and durable anti-tumor activity, as well as a tolerable safety profile, in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.

CLN-081 Elicits Encouraging Efficacy and Safety in EGFR Exon 20–Positive NSCLC

June 4th 2021

CLN-081 demonstrated promising preliminary antitumor activity and an acceptable safety profile across all doses tested in patients with previously treated non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Maintenance Olaparib Maintains PFS Benefit at 5 Years in Ovarian Cancer

March 21st 2021

Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.

Tivozanib Reduces Symptomatic Burden and Toxicity in RCC

February 12th 2021

February 12, 2021 - Tivozanib led to a significantly greater quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy versus sorafenib in patients with metastatic renal cell carcinoma.